Overview

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.
Phase:
PHASE2
Details
Lead Sponsor:
Vera Therapeutics, Inc.
Treatments:
TACI receptor-IgG Fc fragment fusion protein